Initial center experience with the St

Slides:

Advertisements

Similar presentations

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

Advertisements

Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.

ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Open Repair of Ruptured Descending Thoracic and Thoracoabdominal Aortic Aneurysms in 100 Consecutive Cases Mario F. Gaudino, Christopher Lau, Monica Munjal,

How to Avoid Prosthesis-Patient Mismatch

University Heart Center Hamburg

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Aortic Valve Peravalvular Leak. Risk factors for Aortic Valve Peravalvular Leak u Endocarditis u calcified annulus u bicuspid aortic valve –Note many.

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.

Long-term Benefits of Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus on Right Ventricular Function Brent Keeling MD 1, Bradley G. Leshnower.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.

A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.

Presenter: Shoujun Li, Kai Ma Department of Pediatric Cardiac Surgery, Fuwai hospital & National Center for Cardiovascular Disease, PUMC&CAMS, Beijing,

Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.

Objective Bleeding events are grave and sometimes life threatening complications after prosthetic valve replacement, especially in hemodialysis patients.

The Place of Closed Mitral Valvotomy Procedure in Facility Deprived Countries in the Modern PTMC/PMBV Era: 20 Years Experience at SMS Hospital, Jaipur,

1 Heart surgery in Norway 2008 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD

Primary Mitral Regurgitation Degenerative Mitral Valve Disease

Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,

G. Michael Deeb, MD On Behalf of the CoreValve US Investigators

The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Transcatheter Aortic Valve Replacement Andres M. Pineda MD, J. Kevin.

David R. Holmes, MD, FACC, Michael J

On behalf of the FORWARD Study Investigators

Patients Characteristics

Aortic Valve Peravalvular Leak

Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators

Direct Flow Medical Experience with a Conformable, Repositionable, Retrievable, Percutaneous Aortic Valve Reginald Low MD University of California,Davis.

Lako S, Daka A, Nurka T, Dedej T, Memishaj S

David R. Holmes, MD, Michael J

MedStar Washington Hospital Center Cardiac Catheterization Conference

30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.

First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.

Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.

Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,

Table 1 : Baseline Characteristics

Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.

TAVI „Catch me if you can!“

E. Martinelli DVM; P. Brambilla DVM, PhD; C. Locatelli DVM, PhD; S

Figure 1 Representative transoesophageal echocardiographic images of ventricular fibrillation during cardiopulmonary bypass. (A) Mid-oesophageal aortic.

Figure 1: Correlation of plasma ET-1 levels with LAD in patients with mitral valve disease. r is Pearson’s correlation coefficient. ET-1: endothelin 1;

Choosing the valve type for AVR in old patients.

CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,

Mohamed Eid Fawzy, FRCP, FACC, FESC October 6 University Cairo, EGYPT

One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.

Risk of post-operative stroke in patients with known extra-cranial carotid artery disease undergoing Non-Cardiac Surgery Heart and Vascular.

Jan L.Svennevig, MD,PhD Heart surgery in Norway 2007 Norwegian Association of Cardiothoracic Surgeons Jan L.Svennevig, MD,PhD.

University Heart Center Hamburg

Open Repair of Ruptured Descending Thoracic and Thoracoabdominal Aortic Aneurysms in 100 Consecutive Cases Mario F. Gaudino, Christopher Lau, Monica Munjal,

Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry

Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators

Sorin Bicarbon: 17 years of clinical use

Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G

New-Onset Postoperative Atrial Fibrillation and Long-Term Survival After Aortic Valve Replacement Surgery Giovanni Filardo, PhD, MPH, Cody Hamilton,

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.

Where is the common sense in aortic valve replacement

The St Jude Medical Trifecta aortic pericardial valve: Results from a global, multicenter, prospective clinical study Joseph E. Bavaria, MD, Nimesh D.

Early hemodynamic performance of the third generation St Jude Trifecta aortic prosthesis: A systematic review and meta-analysis Kevin Phan, BS, Hakeem.

David R. Holmes, MD, Michael J

Rapid-deployment valves: Finally the fog is lifting-benefits beyond crossclamp and bypass times Günther Laufer, MD, PhD, Dominik Wiedemann, MD, Walter.

Conventional redo biological valve replacement over 20 years: Surgical benchmarks should guide patient selection for transcatheter valve-in-valve therapy

Replacement of Valve Prosthesis Within Aortic Composite Graft

Thomas A. Treibel et al. JACC 2018;71:

Procedural Characteristics

A. Procopi, N. Procopi, JP Collet, O. Barthelemy, P. Leprince, R

Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.

Presentation transcript:

Initial center experience with the St Initial center experience with the St. Jude Trifecta aortic valve prosthesis and Cor-Knot suture fixation device Karan Sian MBBS, Stuart Sugito BMed, Sheila Li BMed, Ajay I Iyengar MBBS PhD, Ross Mejia FRACS, Peng W Seah FRACS Department of Cardiothoracic Surgery, John Hunter Hospital, New Lambton, New South Wales, Australia Corresponding Author: Karan Sian, Department of Cardiothoracic Surgery John Hunter Hospital, 1 Lookout Rd, New Lambton, 2305, NSW, Australia. Tel: +612 4921 3000; email: ksia3999@gmail.com INTRODUCTION: The Trifecta valve*is a tri-leaflet stented pericardial valve made for use in the supra-annular aortic position. The Cor-Knot** is a suture fixation device conceived for remote suture tensioning and quick fixation. This study evaluates the initial experience using the Cor-Knot device and early hemodynamic performance of the Trifecta valve. RESULTS: Concomitant procedures included: mitral valve replacement (2), coronary artery bypass grafting (10) and redo AVR (4). In-hospital mortality at 30 days was 3%(1). Table 2 outlines mean and peak valve gradients per valve size. Cor-Knot demonstrated a mean reduction in total cardio pulmonary bypass and cross-clamp times of (Table 3) however no statistical significance could not be shown. No paravalvular leak or significant aortic regurgitation was demonstrated before discharge. Mean effective orifice valve areas (EOAs) slightly less than those from St. Jude data(1). METHODS: Twenty-nine patients underwent aortic valve replacement (AVR) between Nov. 2013 and July 2015 (Table 1). Cor-Knot was used in 40% (11) of patients. Echocardiography was performed prior to discharge from hospital. Linear regression was used to assess influence of Cor-Knot on bypass and cross clamp times***. Table 2 Echocardiographic data per valve size Valve Size 21(5) 23(16) 25(7) 27(1) 29(1) Peak Gradient (mmHg) 20.32 +/- 5.6 17.4 +/- 6.8 17.86 +/- 1.9 10 7 Mean Gradient (mmHg) 10.106 +/- 1.9 9.17 +/- 3.8 8.77+/-1.4 NR Number of patients given in parentheses CONCLUSIONS: Initial clinical experience and early hemodynamic values of the Trifecta valve are promising. The Cor-Knot has simplified the securement of the bioprosthesis to annulus, no paravalvular leak was demonstrated. Further studies with larger patient cohorts will be required to demonstrate a significant benefit in the reduction of bypass and cross-clamp times when using Cor-Knot. REFERENCES: 1. Permanyer E, Estigarribia AJ, Ysasi A, Herrero E et al. St. Jude Medical Trifecta aortic perioperative performance in 200 patients. Interact CardioVasc Thorac Surg 2013;17:669-673 Table 1 Baseline Patient Characteristics Variables Overall (n=29) Age, mean +/- SD 72.03 +/- 7.07 Sex, female (%) 7 (24.14) BSA, mean +/- SD (m2) 2.01 +/-0.21 BMI, mean +/- SD (kg/m2) 30.31 +/- 6.19 Hypertension (%) 23 (79.31) Diabetes Mellitus (%) 10 (34.48) COPD (%) 3 (10.34) Hyperlipidaemia (%) 20 (68.97) Creatinine, mean +/- SD (mg/dl) 112.17 +/- 74.18 Peripheral vascular disease (%) 1 (3.45) Atrial Fibrillation (%) EuroSCORE, mean +/- SD (%) 2.53 +/- 1.41 *St. Jude Medical Inc., St. Paul, MN, USA **LSI Solutions, Victor, NY, USA ***IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.